Parkinsons Disease Dementia is probably the best if not the only real threat of a meaningful trial result near term. Top line results possible/probable around April imho. Several more months from then to analyze though.
New IND’s are unlikely imho. Enough irons in the fire already.
The cycle will begin soon where Anavex will being receiving ~40% of every dollar they have spent so far on the Alzheimer’s trial as a rebate. Kind of a secondary source of income in a certain sense.
To my knowledge, Anavex has been very opaque in revealing their trial budgets. It might be possible to figure out how much Anavex has spent on the Alzheimer’s trial by the amount rebated, even if they don’t disclose the expenditures explicitly.
I personally expect that the filing will show that Anavex has been tapping Cantor to maintain the cash balance. That would be the smart strategy imho.
Consider anyone who even knows what an XR7 is as a kindred spirit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.